Zacks: Brokerages Anticipate Teladoc Health, Inc. (NYSE:TDOC) Will Announce Quarterly Sales of $543.47 Million

Analysts expect Teladoc Health, Inc. (NYSE:TDOC) to post sales of $543.47 million for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have made estimates for Teladoc Health’s earnings, with the lowest sales estimate coming in at $540.30 million and the highest estimate coming in at $548.86 million. Teladoc Health reported sales of $383.32 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 41.8%. The business is scheduled to announce its next earnings report on Wednesday, February 23rd.

According to Zacks, analysts expect that Teladoc Health will report full year sales of $2.02 billion for the current year, with estimates ranging from $2.02 billion to $2.03 billion. For the next financial year, analysts anticipate that the company will post sales of $2.59 billion, with estimates ranging from $2.55 billion to $2.61 billion. Zacks’ sales averages are an average based on a survey of research analysts that cover Teladoc Health.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, October 27th. The health services provider reported ($0.53) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.70) by $0.17. The firm had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $516.79 million. Teladoc Health had a negative net margin of 43.60% and a negative return on equity of 1.47%. Teladoc Health’s quarterly revenue was up 80.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.13) EPS.

Several research firms have commented on TDOC. Needham & Company LLC lowered their target price on shares of Teladoc Health from $205.00 to $170.00 and set a “buy” rating on the stock in a research note on Thursday, October 28th. Oppenheimer lowered their price objective on shares of Teladoc Health from $200.00 to $185.00 and set an “outperform” rating on the stock in a research note on Friday, November 19th. Cantor Fitzgerald lowered their price objective on shares of Teladoc Health from $185.00 to $150.00 and set a “neutral” rating on the stock in a research note on Thursday, October 28th. Craig Hallum lowered their price objective on shares of Teladoc Health from $165.00 to $150.00 and set a “hold” rating on the stock in a research note on Thursday, October 28th. Finally, Bank of America lowered their price objective on shares of Teladoc Health from $175.00 to $160.00 and set a “neutral” rating on the stock in a research note on Thursday, October 28th. Fifteen investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $181.56.

In other Teladoc Health news, insider Arnnon Geshuri sold 4,050 shares of Teladoc Health stock in a transaction that occurred on Thursday, August 26th. The shares were sold at an average price of $143.29, for a total value of $580,324.50. Following the completion of the sale, the insider now directly owns 88,908 shares in the company, valued at $12,739,627.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Stephany Verstraete sold 1,000 shares of Teladoc Health stock in a transaction that occurred on Wednesday, November 3rd. The shares were sold at an average price of $154.25, for a total transaction of $154,250.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,269 shares of company stock valued at $3,382,701. 6.47% of the stock is currently owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in Teladoc Health during the first quarter worth $5,346,000. Spence Asset Management increased its position in Teladoc Health by 0.8% during the second quarter. Spence Asset Management now owns 93,373 shares of the health services provider’s stock worth $15,527,000 after acquiring an additional 734 shares during the period. Capital Advisors Inc. OK increased its position in Teladoc Health by 11.9% during the second quarter. Capital Advisors Inc. OK now owns 73,681 shares of the health services provider’s stock worth $12,252,000 after acquiring an additional 7,855 shares during the period. Koss Olinger Consulting LLC increased its position in Teladoc Health by 166.7% during the second quarter. Koss Olinger Consulting LLC now owns 20,000 shares of the health services provider’s stock worth $3,326,000 after acquiring an additional 12,500 shares during the period. Finally, State of Wisconsin Investment Board increased its position in Teladoc Health by 14.5% during the second quarter. State of Wisconsin Investment Board now owns 66,714 shares of the health services provider’s stock worth $11,094,000 after acquiring an additional 8,432 shares during the period. 80.67% of the stock is currently owned by institutional investors.

Teladoc Health stock traded up $3.18 during trading hours on Friday, hitting $106.41. 201,301 shares of the company traded hands, compared to its average volume of 3,031,808. The firm has a market cap of $17.03 billion, a P/E ratio of -18.35 and a beta of 0.33. The company has a quick ratio of 3.64, a current ratio of 3.83 and a debt-to-equity ratio of 0.08. The firm’s 50-day simple moving average is $136.04 and its two-hundred day simple moving average is $144.75. Teladoc Health has a 1-year low of $102.12 and a 1-year high of $308.00.

About Teladoc Health

Teladoc Health, Inc engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure.

Read More: What is a stock buyback?

Get a free copy of the Zacks research report on Teladoc Health (TDOC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.